A 52-year-old male farmer from Punjab with a 6-month history of progressive weight loss, fever, and productive cough is found to have a cavitary lesion in the right upper lobe on chest X-ray. Sputum smear microscopy is positive for acid-fast bacilli. Transbronchial biopsy shows caseating granulomas. Tuberculosis is confirmed. The patient is started on standard first-line anti-tuberculous therapy. At 2 weeks of treatment, he develops severe headache, neck stiffness, and altered mental status. CSF analysis shows lymphocytic pleocytosis with low glucose and elevated protein. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Tuberculous Meningitis (TBM) This patient has classic TBM: active pulmonary TB + meningeal symptoms + CSF findings (lymphocytic pleocytosis, low glucose, high protein). TBM is the most severe form of extrapulmonary TB. ## Why Dexamethasone? **Key Point:** Dexamethasone is the single most important adjunctive therapy in TBM. It reduces mortality and disability by: 1. Reducing vasculitis and meningeal inflammation 2. Decreasing intracranial pressure and risk of hydrocephalus 3. Improving CSF penetration of anti-TB drugs 4. Reducing spinal cord compression and cranial nerve palsies **High-Yield:** Dexamethasone should be started IMMEDIATELY upon clinical suspicion of TBM — do NOT wait for culture confirmation. Early initiation (within first 2 weeks of ATT) is critical for outcome. ## Dosing and Duration ```mermaid flowchart TD A[Suspected TBM]:::outcome --> B[Start dexamethasone 0.3-0.4 mg/kg/day]:::action B --> C{Duration based on severity}:::decision C -->|Severe/Miliary| D[8 weeks total]:::action C -->|Non-severe| E[4-6 weeks total]:::action D --> F[Taper over 2-4 weeks]:::action E --> F F --> G[Continue standard ATT]:::action ``` **Mnemonic: TBM-DEXAMETHASONE** = **D**ose early, **E**ssential for survival, **X**-ray brain to exclude mimics, **M**eningitis requires adjunctive steroids, **E**valuate CSF, **T**herapy: ATT + dexamethasone, **H**igh mortality without steroids, **A**djunct to first-line drugs, **S**evere inflammation reduced, **O**utcome improved, **N**eurological sequelae prevented, **E**arly initiation critical. ## Why NOT the Other Options? | Option | Why Incorrect | |--------|---------------| | Fluoroquinolone + high-dose INH | Fluoroquinolones are second-line agents; first-line drugs (HRZE) have excellent CSF penetration. High-dose INH is not standard and does not address the inflammatory component of TBM. | | MRI brain before dexamethasone | While MRI may show meningeal enhancement or hydrocephalus, it should NOT delay dexamethasone initiation. Clinical diagnosis + CSF findings are sufficient; imaging is confirmatory, not prerequisite. | | Switch to second-line drugs | Second-line drugs are reserved for drug-resistant TB (MDR/XDR). This patient has drug-susceptible TB (no resistance history). Standard first-line ATT is appropriate; the addition of dexamethasone is the key intervention. | **Clinical Pearl:** TBM is a medical emergency with mortality up to 20–30% even with treatment. The combination of standard ATT + dexamethasone reduces mortality to ~5–10%. Delay in steroid initiation is associated with worse neurological outcomes, including permanent disability. **Warning:** Do NOT confuse TBM management with bacterial meningitis. While both require steroids, TBM requires continuation of ATT (not antibiotics alone) and longer steroid duration (4–8 weeks vs. 2–4 days). [cite:Harrison 21e Ch 158; Robbins 10e Ch 15]